Pasithea Therapeutics (KTTA) Short Interest Ratio & Short Volume

Short interest is the volume of Pasithea Therapeutics shares that have been sold short but have not yet been closed out or covered. As of October 15th, traders have sold 22,800 shares of KTTA short. 2.84% of Pasithea Therapeutics' shares are currently sold short. Learn More on Pasithea Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.84% of Pasithea Therapeutics' floating shares are currently sold short.

Pasithea Therapeutics saw a decline in short interest during the month of October. As of October 15th, there was short interest totaling 22,800 shares, a decline of 86.7% from the previous total of 171,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Pasithea Therapeutics currently has issued a total of 1,040,000 shares. Some of Pasithea Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Pasithea Therapeutics currently has a public float of 802,500 shares.

2.84% of Pasithea Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Pasithea Therapeutics: Vaccinex, Inc. (2.46%), Talphera, Inc. (0.21%), Marinus Pharmaceuticals, Inc. (6.34%), Chemomab Therapeutics Ltd. (0.74%), NLS Pharmaceutics Ltd. (2.88%), Tenax Therapeutics, Inc. (0.70%), Trinity Biotech plc (1.12%), Mannatech, Incorporated (0.21%), PharmaCyte Biotech, Inc. (0.30%), Aspira Women's Health Inc. (4.03%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.14 billion), AppLovin Co. ($3.15 billion), Paychex, Inc. ($2.69 billion), Nu Holdings Ltd. ($2.48 billion), Cencora, Inc. ($2.24 billion), International Paper ($2.04 billion), Tractor Supply ($1.96 billion), Coinbase Global, Inc. ($1.93 billion), Moderna, Inc. ($1.91 billion), and SoFi Technologies, Inc. ($1.84 billion). View all of the most shorted stocks.

Short selling KTTA is an investing strategy that aims to generate trading profit from Pasithea Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Pasithea Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of KTTA, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KTTA, twice per month. The most recent reporting period available is October, 15 2024.